Although substantial variability was observed between individual-level tau PET change and individual-level plasma p-tau217 change, their overall association suggests that changes in plasma p-tau217 may be a useful secondary outcome in clinical trials targeting AD pathology, as was performed in the phase II donanemab trial37 and the lecanemab phase III trial.4 This evidence concerns the gene MAPT and Alzheimer disease.